

NITYR® (nitisinone) Tablets Enrollment Form





Phone: +1 (888) 360-8482 (VITA) FAX: +1 (888) 385-8482 (VITA) Website: www.cyclevita.life | www.nityr.us

4 DATIFUT INFORMATION												
1. PATIENT INFORMATION												
Patient Name (First, Last):	Date of Birth:					Gender:						
Street Address:			City:				ZIP:					
Email Address:	Cell Phone:			Home Phone:		Preferred Language:						
Caregiver Name (if applicable):	Relation to patient:				Caregiver Phon	ne (if different from patient):						
2. INSURANCE INFORMATION (attach front and back copie.	s of all insura	ance card	ls)	Patient/Family does	NOT have insu	ırance 🔲	Patient is a NEWBORN					
Primary Insurance Company Name:			ardholder Name:		Relation to Pat							
Primary Insurance Policy Number:	Primary Ins	urance G	roup Number:		Primary Insurance Phone Number:							
Pharmacy Plan Name:	PCN Number:				BIN Number:							
Pharmacy Plan Policy Number:	Pharmacy Plan Group Number:				Pharmacy Phone Number:							
Secondary Insurance Plan Name:	Secondary Insurance Cardholder Name:				Relation to Patient:							
Secondary Insurance Policy Number:	Secondary	Insurance	e Group Number:		Secondary Insurance Phone Number:							
3. PRESCRIBER INFORMATION												
Prescriber Name (First, Last):			Facility/Clinic Name:									
State Medical License Number:			NPI Number:									
Facility/Clinic Street Address:			City:			State:	ZIP:					
Facility Shipping Address:			above City:			State:	ZIP:					
Prescriber Email:	Prescriber Phone Number:				Prescriber FAX:							
Dietitian or Office Contact Name (First, Last): Dietitian or Office Contact					fice Contact Phone Number:							
4. PATIENT MEDICAL INFORMATION												
Primary Diagnosis:		Diagnosis Code:	☐ ICD-10: ☐ Other:	E70.21 (HT-1)	☐ ICD-10: E70.29 (AKU)							
Patient Weight:		Patient is currently on a tyrosine and phenylalanine restricted diet?:										
Liver transplanted?: Yes No *If yes, provide transplant date:												
Allergies: NKDA Known:												
Current Medications: None Known:												

Page 1 of 2 $\,$

Confidentiality Statement: This facsimile is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately and call +1 (888) 360-8482 to obtain instructions as to the proper destruction of the transmitted material.

NITYR® (nitisinone) Tablets Enrollment Form





Phone: +1 (888) 360-8482 (VITA) FAX: +1 (888) 385-8482 (VITA) Website: <u>www.cyclevita.life</u> | <u>www.nityr.us</u>

Patient Name (Printed):						Date of Birth:			
5. PRESCRIPTION	cialty Pharma	cy:							
Patient's Full Name (First, Middle Initi		Date of Birth	:						
Ship to: Prescriber's Office Hospital Pharmacy Patient Residence: First Fill Always Never									
"Quick Start" (Please check this box if the below statement applies to this patient) "Quick Start" is a FREE supply of NITYR® (nitisinone) Tablets that allows eligible patients to begin therapy immediately while Cycle Vita™ secures appropriate benefit verification and authorization. If Quick Start is selected for the patient, an initial 14-day supply of NITYR® (nitisinone) Tablets will be dispensed; 28-day initial supply for patients 6 months and younger. The strength, directions and quantity will match the written prescription below. All further Quick Start deliveries will be supplied in 14-day refills (with a limit of 56 days of FREE supply).									
Ongoing Prescription (Check this	-	,							
2mg NITYR® (nitisinone) Table	ets (NDC: 70709-002-60)	□ 5mg NITYR® (ni	itisinone) Tablets (NDC: 707	709-005-60)	☐ 10mg NI1	「YR® (nitisinone)	Tablets (NDC: 70709	-000-60)	
Dosage Instructions:		Dosage Instructions:		Dosage Instructions:					
AM	PM		AM	PM		AM		_ PM	
Quantity: Ref	fills:	Quantity:	Refills:		Quantity:		Refills:		
Date:			Date:			Date:			
Dispense as Written: x Dispense as Writte			x	Dispense as Written: x					
The prescriber is to comply with their state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.									
6. ADMINSTRATION INSTR	HETIONS								
Morning	Patient CAN swa	llow tablet(s)		Patier	nt CANNOT sw	vallow tablets			
2mg tablet(s) and									
——— 5mg tablet(s) and	☐ Take tablet(s) with or without food		Suspend in an oral s	ENSION) Crush and mix with applesauce					
10mg tablet(s) and			Create a suspension us mL* of water. Fol	•					
Afternoon									
2mg tablet(s) and			*use 2.6mL for (1) tab tablets; an oral syringe						
——— 5mg tablet(s) and									
10mg tablet(s) and									
Special Instructions:									
Prescriber Declaration: I verify that the patient and prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed NITYR® (nitisinone) Tablets based on my professional judgment of medical necessity. I authorize CYCLE Pharmaceuticals or its affiliated companies or subcontractors, including in-network specialty pharmacies, through the Cycle Vita™ − NITYR® (nitisinone) Tablets Program ("the Program") to forward this prescription by facsimile, or by mail to the relevant in-network pharmacy for the above-named patient. I also authorize the Program to perform any steps necessary to obtain reimbursement for NITYR® (nitisinone) Tablets, including but not limited to insurance verification and authorization. I understand that the Program may need additional information, and I agree to provide it as needed for the purposes of reimbursement. I also authorize the Program to perform any steps necessary to obtain reimbursement for NITYR® (nitisinone) Tablets, including but not limited to insurance verification and authorization to facilitate a coverage decision. Prescriber's signature (sign below) (Physician attests this is his/her legal signature. NO STAMPS.) Prescriber Signature: X									

Page 2 of 2

Confidentiality Statement: This facsimile is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately and call +1 (888) 360-8482 to obtain instructions as to the proper destruction of the transmitted material.